About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01585805

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Study identifier: NCT01585805
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

Male or female patients with locally advanced or metastatic pancreas adenocarcinoma with BRCA1 or 2 or PALB2 mutation.

Type of study:

Phase II study

Treatment:

Patients will receive one of the following treatments:

  • 21-day cycles with veliparib orally on days 1-12, gemcitabine hydrochloride intravenously and cisplatin intravenously on days 3 and 10
  • 21-day cycles with gemcitabine hydrochloride intravenously and cisplatin intravenously on days 3 and 10
  • 28-day cycles with veliparib orally on days 1-28

Study sites:

Illinois
Chicago
Northwestern University
Principal Investigator: Mary F. Mulcahy
Contact: Mary F. Mulcahy 312-695-4440 m-mulcahy@northwestern.edu

University of Chicago Comprehensive Cancer Center
Principal Investigator: Hedy L. Kindler
Contact: Hedy L. Kindler 773-834-7424 hkindler@medicine.bsd.uchicago.edu

Harvey
Ingalls Memorial Hospital Recruiting
Principal Investigator: Mark F. Kozloff
Contact: Mark F. Kozloff 708-339-4800 mkozloff@bsd.uchicago.edu

Maryland
Baltimore
University of Maryland Greenebaum Cancer Center
Principal Investigator: Yixing Jiang
Contact: Yixing Jiang 410-328-7225 yjiang@umm.edu

Massachusetts
Boston
Dana-Farber Cancer Institute Recruiting
Contact: Robert J. Mayer 617-632-3473 robert_mayer@dfci.harvard.edu

Michigan
University of Michigan University Hospital
Principal Investigator: Mark M. Zalupski
Contact: Mark M. Zalupski 734-615-3969 zalupski@umich.edu

Missouri
Saint John's Mercy Medical Center
Principal Investigator: Bethany G. Sleckman
Contact: Bethany G. Sleckman 314-251-7057 slecbg@stlo.mercy.net

New York
New York
Memorial Sloan-Kettering Cancer Center
Principal Investigator: Eileen M. O'Reilly
Contact: Eileen M. O'Reilly 212-639-6672 oreillye@mskcc.org

Canada
Ontario
Ontario Cancer Institute at Princess Margaret Hospital
Principal Investigator: Malcolm J. Moore
Contact: Malcolm J. Moore 416-946-4501 clinical.trials@uhn.on.ca

Israel
Jerusalem
Shaare Zedek Medical Center
Contact: Amiel Segal 972-2-666-6331 segal@szmc.org.il

Tel Hashomer
Chaim Sheba Medical Center
Contact: Talia Golan 972-3-530-3030 tailia.golan@sheba.health.gov.il

Page updated 04/06/14

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org